Pfizer selects ICON and Parexel as preferred partners
This article was originally published in Scrip
Executive Summary
Pfizer has chosen the CROs ICON Clinical Research and Parexel International as its two preferred drug development partners, as it seeks to streamline its R&D dollar commitment.